Key South Swedish life science stakeholders call for targeted investment in pandemic related R&D

Dec 11, 2020

In today´s edition of Dagens Medicin Sweden, a handful of key stakeholders in South Swedish life science, including MVA CEO, Petter Hartman, call for the Swedish government to prioritize pandemic-related R&D, focus on on Sweden as an attractive destination for clinical trials and improve the framework conditions for the commercialisation of life science R&D for small and medium-sized companies.

The other co-authors of the opinion piece (in Swedish) are:

Christina Östberg Lloyd, CEO, Pharmiva AB,
Sofia Gerward, Head of Medical Affairs Novo Nordisk Scandinavia AB,
Charlotte Ahlgren Moritz, Pro-vice-chancellor, Malmö universitet
Heiko Herwald, professor, Vice dean at Faculty of Medicine, Lunds Universitet
Helene Norberg, Director, Analysis and Sustainability, City of Malmö
Sylvie Bove, Director, Business Development & Innovation, dep. of life science and health, RISE
Ulrika Geeraedts, Director of Regional Development at Region Skåne

 

Most recent news